Patient dosing has begun in Zion Pharma‘s Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast cancer and other solid tumors. “We are excited to have initiated our Phase 1 trial for ZN-A-1041,” Zack Cheng, PhD, chairman, CEO, and co-founder of Zion Pharma, said in a press release. HER2 (human epidermal growth factor receptor 2) is a protein that promotes the…
You must be logged in to read/download the full post.
The post Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor appeared first on BioNewsFeeds.